Arteriosclerosis, Vol 8, 57-67, Copyright © 1988 by American Heart Association
ARTICLES |
H Robenek and G Schmitz
Medical Faculty, Westfalische-Wilhelms-University, Munster, West Germany.
The effects of the slow Ca++ channel blocker, nifedipine, and ACAT inhibitor, octimibate, on cholesterol-loaded macrophages were compared at the ultrastructural level. The Ca++ antagonist induced the formation of membrane-surrounded "lamellar bodies" originating from lysosomes. The macrophages secreted these lamellar bodies, which were rich in phospholipids and cholesterol, into the culture medium even in the absence of cholesterol acceptors. In contrast, the ACAT inhibitor induced the formation of lamellar bodies originating from lipid droplets, which were also surrounded by membranes. There is strong evidence that these latter membranes were newly synthesized at the margin of the lipid droplets by the endoplasmic reticulum. The lamellar bodies descending from lipid droplets after ACAT inhibitor treatment were not secreted by the cells. They were stored in the cytoplasmic compartment in the absence of high density lipoproteins (HDL). When HDL were added to the medium, the lamellar bodies specifically interacted with endosomes containing the internalized HDL particles and disappeared concomitantly with an enhanced HDL-mediated cholesterol efflux. From the biochemical data in the accompanying article and the morphological data here, we conclude that macrophages release cholesterol by two major pathways: 1) an HDL-independent secretion of lamellar bodies containing cholesterol, which originate from lysosomes, and 2) an HDL-dependent release of cholesterol via the formation of lamellar bodies descending from lipid droplets, which intracellularly fuse with HDL-containing endosomes. The cholesterol-enriched HDL are then secreted as intact lipoproteins.
This article has been cited by other articles:
![]() |
D. E. Dove, Y. R. Su, W. Zhang, W. G. Jerome, L. L. Swift, M. F. Linton, and S. Fazio ACAT1 Deficiency Disrupts Cholesterol Efflux and Alters Cellular Morphology in Macrophages Arterioscler Thromb Vasc Biol, January 1, 2005; 25(1): 128 - 134. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. S. Kruth, I. Ifrim, J. Chang, L. Addadi, D. Perl-Treves, and W.-Y. Zhang Monoclonal antibody detection of plasma membrane cholesterol microdomains responsive to cholesterol trafficking J. Lipid Res., September 1, 2001; 42(9): 1492 - 1500. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Öörni, M. O. Pentikäinen, M. Ala-Korpela, and P. T. Kovanen Aggregation, fusion, and vesicle formation of modified low density lipoprotein particles: molecular mechanisms and effects on matrix interactions J. Lipid Res., November 1, 2000; 41(11): 1703 - 1714. [Abstract] [Full Text] |
||||
![]() |
W.-Y. Zhang, P. M. Gaynor, and H. S. Kruth Apolipoprotein E Produced by Human Monocyte-derived Macrophages Mediates Cholesterol Efflux That Occurs in the Absence of Added Cholesterol Acceptors J. Biol. Chem., November 8, 1996; 271(45): 28641 - 28646. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Guyton and K. F. Klemp Development of the Lipid-Rich Core in Human Atherosclerosis Arterioscler Thromb Vasc Biol, January 1, 1996; 16(1): 4 - 11. [Full Text] |
||||
![]() |
D. N. Mukhin, F.-F. Chao, and H. S. Kruth Glycosphingolipid Accumulation in the Aortic Wall Is Another Feature of Human Atherosclerosis Arterioscler Thromb Vasc Biol, October 1, 1995; 15(10): 1607 - 1615. [Abstract] [Full Text] |
||||
![]() |
J. F. Reindel, M. A. Dominick, T. M.A. Bocan, A. W. Gough, and E. J. Mcguire Toxicologic Effects of a Novel Acyl-CoA: Cholesterol Acyltransferase Inhibitor in Cynomolgus Monkeys Toxicol Pathol, September 1, 1994; 22(5): 510 - 518. [Abstract] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1988 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |